Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24.94 USD | +8.43% | +6.75% | -18.53% |
02:56pm | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
04-15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.53% | 2.22B | |
+24.41% | 46.71B | |
+48.83% | 41.8B | |
-0.87% | 41.52B | |
-5.86% | 29.55B | |
+11.21% | 25.78B | |
-20.90% | 19.26B | |
+2.98% | 12.14B | |
-2.17% | 12.08B | |
+30.59% | 11.98B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Transcript : Intellia Therapeutics, Inc., Q4 2023 Earnings Call, Feb 22, 2024